114/10/29 19:00 - 20:30

-

線上課程

時段	主題	講師	主持人
19:00~19:05	Opening		裴馰 醫師 輔大醫院 內分泌新陳代謝科
19:05~20:05	Beyond Glycemic Control: SGLT2 inhibitor as a Cornerstone for HF Risk Reduction in Diabetic Patients	王宇澄 醫師 亞大醫院 心臟科	裴馰 醫師 輔大醫院 內分泌新陳代謝科
20:05~20:30	Panel discussion & Closing	ALL	ALL

Heart failure (HF) represents one of the earliest and most burdensome cardiovascular complications in patients with type 2 diabetes mellitus (T2DM). Despite advances in glucose-lowering therapies, the risk of HF remains high, underscoring the need for preventive interventions. Canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, has emerged as a key therapeutic agent with cardioprotective effects beyond glycemic control. Evidence from large-scale clinical trials, including the CANVAS Program and CREDENCE study, demonstrated that Canagliflozin significantly reduces hospitalization for heart failure and provides benefits even in individuals without prior HF. The mechanisms of protection are thought to involve osmotic diuresis and natriuresis, leading to reduced plasma volume and lower cardiac preload and afterload, as well as improvements in myocardial energetics, endothelial function, and renal hemodynamics. These combined effects contribute to better cardiovascular stability and early prevention of HF in diabetic patients. In clinical practice, Canagliflozin thus represents a valuable option for proactive management of T2DM patients at risk for HF, reinforcing its role in integrated cardiometabolic care and shifting the paradigm from treatment of established disease to prevention of first events.

線上課程

-

-

中華民國醫師公會全國聯合會專業1.2積分
社團法人中華民國藥師公會全國聯合會
中華民國糖尿病學會
社團法人中華民國糖尿病衛教學會乙類1分
台灣家庭醫學醫學會乙類1分
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》